Back to Agendas
[V1-S4] For Enhancement of Industry-Government-Academia Collaboration in Japan (Part 2)
Session Chair(s)
Hideki Hanaoka, MD, PhD
, Chiba University Hospital, Japan
Toshio Miyata, MD
Executive Director, Health and Global Policy Institute, Japan
In April 2015, AMED, Japan Agency for Medical Research and Development, was established to enhance efficient research and development, from the basic scientific research to practical application, with consistency in the field of health care science in Japan. Creating innovative drugs from Japan is one of the most important elements of Japan’s growth strategy and a great chance for pharmaceutical industry at the same time. In this session, experts from academic departments, industry, and government will facilitate discussions on the challenges we have in collaboration among them, sharing the excellent practices from several ongoing activities.
Speaker(s)
Shunichi Takahashi, PhD
Director, Head of Open Innovation Center Japan, Bayer Yakuhin, Ltd., Japan
Bayer’s R&D Partnering Models
Tohru Yoshikawa
Webmaster of DSANJ, Life Science Group, Economy and Industry Division , Osaka Chamber of Commerce and Industry, Japan
Introduction of The DSANJ System –Scientific-Based Trust-Cultivating System in The Drug-Discovery Stage in Japan-
Mitsuhiro Okamoto, RPh
Associate Director, HR Development, Development Management Dept, Takeda Pharmaceutical Company Limited, Japan
Goal to Reach for ARO in Japan
Kazuhiro Momose
Senior Manager, Astellas Pharma Inc., Japan
Have an account?